Unknown PHASE1 INTERVENTIONAL 2-arm NCT04438720

Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects

Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects: A Single-dose and Two-period Crossover Study

Sponsor: Cao Yu

Conditions Therapeutic Equivalency

Interventions Extended Release Nifedipine Tablets 30 mg Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)

Updated 6 times since 2020 Last updated: Aug 20, 2020 Started: Jun 25, 2020 Primary completion: Sep 9, 2020 Completion: Sep 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Therapeutic Equivalency, this trial is ongoing. The trial is conducted by Cao Yu and has accumulated 6 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Recruiting PHASE1
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jul 2020 — Sep 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cao Yu

Data source: The Affiliated Hospital of Qingdao University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Qingdao, China